Thanks, James, for digging up the papers. It answered my question of how they managed to get the drug for the study before the drug was approved by the FDA:
The current study was performed with Celebrex, the COX-2 compound from G. D.
Searle and Co. that was approved for sale on December 31, 1998, by the Food and
Drug Administration. FitzGerald notes, however, that the potential risk factor
identified in the experiments done in his laboratory is not a property solely of
Celebrex. Results of a study involving Vioxx, a COX-2 inhibitor from Merck & Co.,
have shown similar results, he says.
The lead author on the study is B. F. McAdam, MD. In addition to senior author
FitzGerald, the remaining authors are F. Catella-Lawson, MD; I. A. Mardini, MD; S.
Kapoor, PhD; and J. A. Lawson, BS. Funding for the study was provided by G. D.
Searle and Co.
|
